Stockscreener 앱 받기
1.63
2.40%
-0.04
시간 외 거래:
1.63
전일 마감가:
$1.67
열려 있는:
$1.68
하루 거래량:
316.16K
Relative Volume:
0.36
시가총액:
$157.60M
수익:
$69.56M
순이익/손실:
$-240.05M
주가수익비율:
-0.5525
EPS:
-2.95
순현금흐름:
$-121.90M
1주 성능:
+1.87%
1개월 성능:
-7.39%
6개월 성능:
-44.56%
1년 성능:
-65.25%
1일 변동 폭
$1.62
$1.72
1주일 범위
$1.62
$1.77
52주 변동 폭
$1.39
$5.38
Adc Therapeutics Sa Stock (ADCT) Company Profile
명칭
Adc Therapeutics Sa
전화
41 21 653 02 00
주소
BIOPOLE, EPALINGES
ADCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
1.63 | 157.60M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-05-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-28 | 개시 | Guggenheim | Buy |
| 2023-08-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-04-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-12-06 | 개시 | CapitalOne | Overweight |
| 2022-11-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-08-17 | 재개 | Jefferies | Buy |
| 2021-08-09 | 개시 | RBC Capital Mkts | Outperform |
| 2021-06-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-12-03 | 개시 | Stifel | Hold |
| 2020-10-29 | 개시 | H.C. Wainwright | Buy |
| 2020-06-09 | 개시 | BofA/Merrill | Buy |
| 2020-06-09 | 개시 | Cowen | Outperform |
모두보기
Adc Therapeutics Sa 주식(ADCT)의 최신 뉴스
ADC Therapeutics SA (NYSE:ADCT) Short Interest Update - MarketBeat
ADC Therapeutics SA (NYSE:ADCT) Sees Large Drop in Short Interest - Defense World
ADC Therapeutics Appoints Jennifer Herron as Chief Commercial Officer -November 05, 2019 at 06:00 am EST - Marketscreener.com
SG Americas Securities LLC Increases Stock Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADCT stock touches 52-week low at $1.42 amid market challenges - MSN
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26% - Simply Wall St
Neuroendocrine Tumors Clinical and Non-Clinical Studies, Key - openPR
Is Adc Therapeutics SA (ADCT) a good investment opportunity? - US Post News
Investing in Adc Therapeutics SA (ADCT) Is Getting More Attractive - Knox Daily
Several ADC Therapeutics Insiders Sell Shares Sending Potential Negative Signal - Simply Wall St
Adc Therapeutics SA (ADCT) Shares Down Despite Recent Market Volatility - The News Heater
Adc Therapeutics SA (ADCT) stock analysis: A comprehensive overview - US Post News
Upward Trajectory: Adc Therapeutics SA (ADCT) Posts a Slidee, Closing at 1.58 - The Dwinnex
The Attractiveness of Investing In Adc Therapeutics SA (ADCT) is Growing - Knox Daily
BlackRock, Inc.'s Strategic Acquisition of ADC Therapeutics SA Shares - GuruFocus.com
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PR Newswire
Strategic Stock Options Grant: ADC Therapeutics Secures Top Talent with 26.8K Share Package - StockTitan
ADC Therapeutics SA (NYSE:ADCT) Stock Holdings Lifted by JPMorgan Chase & Co. - Defense World
ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - BioSpace
ADC Therapeutics Takes Center Stage: Key Investor Presentation Coming at Major Biotech Conference - StockTitan
ADCT stock touches 52-week low at $1.66 amid market challenges - MSN
Brokers Set Expectations for ADCT FY2025 Earnings - Defense World
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Expands By 18.0% - MarketBeat
Barclays PLC Raises Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics SA Reveals Preliminary ZYNLONTA Net Sales Information in Recent Corporate Presentation - Defense World
Institutional owners may consider drastic measures as ADC Therapeutics SA's (NYSE:ADCT) recent US$21m drop adds to long-term losses - Simply Wall St
Jane Street Group LLC Buys 38,859 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics Achieves Profitability with ZYNLONTA - TipRanks
ADC Therapeutics : JP Morgan 43rd Annual Healthcare Conference - Marketscreener.com
ADCT Stock Hits 52-Week Low at $1.71 Amid Market Challenges - Investing.com
Geode Capital Management LLC Buys 128,454 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics (NYSE:ADCT) Receives “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Reiterates "Buy" Rating for ADC Therapeutics (NYSE:ADCT) - MarketBeat
Barclays PLC Buys 93,890 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
Is ADC Therapeutics SA (NYSE:ADCT) Worth US$2.0 Based On Its Intrinsic Value? - Yahoo Finance
ADC Therapeutics Grants Inducement Stock Options to New Employees in Retention Push | ADCT Stock News - StockTitan
ADC spikes after enrollment update on confirmatory trial for lymphoma therapy - MSN
ADC Therapeutics stock rises on enrollment update (ADCT:NYSE) - Seeking Alpha
ADC Therapeutics SA (NYSE:ADCT) Shares Purchased by State Street Corp - Defense World
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Rises By 36.9% - MarketBeat
ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma - PR Newswire
ADC Therapeutics Completes Enrollment in Pivotal ZYNLONTA Lymphoma Trial with 80% Response Rate - StockTitan
Fmr LLC Takes $167,000 Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Charles Schwab Investment Management Inc. Acquires 18,796 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
Top 10 Companies to Watch Out for in Antibody Drug Conjugates - openPR
ADC Therapeutics' SWOT analysis: zynlonta sales challenges offset by expansion hopes - Investing.com
Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development - Yahoo Finance UK
Redmile Group, Llc Acquires 100,000 Shares of ADC Therapeutics SA (NYSE:ADCT) Stock - MarketBeat
Research Analysts Issue Forecasts for ADCT FY2024 Earnings - Defense World
Redmile Group, LLC Increases Stake in ADC Therapeutics SA - GuruFocus.com
FY2024 Earnings Estimate for ADCT Issued By HC Wainwright - MarketBeat
Adc Therapeutics Sa (ADCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):